Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
about
Rhabdomyolysis in association with simvastatin and amiodaronePharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase.Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice dailyRational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review.The prince and the pauper. A tale of anticancer targeted agents.Squalene monooxygenase - a target for hypercholesterolemic therapy.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines.Drug-drug interactions that interfere with statin metabolism.Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin.Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese.Fluvastatin-induced rhabdomyolysis.Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.Physicians' prescribing attitudes to combined therapy with statins and fibrates.Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities.Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice.Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes.Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure.Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.Effects ofGinkgo bilobaextracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices
P2860
Q28168134-50444784-D576-492D-9B00-102909E5A404Q34773911-28904DE8-8EEB-42C3-80B0-F5C77A0BA8D9Q35127790-21734D10-772F-42E2-99AC-E8C41203D59CQ35159559-D1156741-110A-468D-8194-F5409D99A8C1Q35219649-C85802A3-F4F3-4422-A87A-8A78E5C41953Q36965617-5DEF4C34-5C20-46D6-B84B-E06408D095CBQ37042365-F9AD5660-0F13-4B02-8C2F-04C04DDC6CAEQ37952270-30CAAEDC-384C-491D-921F-2A36486C460FQ37955160-4B773CD8-29F4-48F9-BC54-727A9A049DEFQ38050686-3565B4B5-6AA6-4110-A5A7-F889FA1F0F16Q38109095-472EF04E-B3FF-4308-B131-5A66BA7EC3AFQ38360942-F7E5E601-A359-4E63-ADC9-FBCE3733F903Q38522299-C6567F64-279B-4C78-92B4-7FAA7957F804Q39997801-021E8DF3-9AF1-4497-A748-6D0521F29654Q42111497-12702E0D-7590-492A-9DAF-D8EBF114A791Q42284181-887F97DA-B246-4E4C-A1C8-8D3213E7C31BQ44229921-98441E6E-195A-4E97-843B-DFAEB4F11BB7Q44300036-DF2B650F-17E8-4DBC-B6B7-C065F4AC9042Q44677374-4F9EB021-397A-421A-A074-0CCC33BF9F7FQ44999818-18289935-C7F3-4BE0-A8DE-BCBB880FFFFEQ45001398-ABFAB61A-DDC5-420E-8E8C-55804B1125FAQ46699493-E1D742FB-2CAE-4E43-A9C6-AC44760BEF5AQ50712735-10D3E792-0E90-4144-9D17-1C4CE4D68BC5Q51304354-786DA88F-E683-4DFF-BBC0-032842EC8698Q53581879-F6EE654E-A4F4-40B2-8D5F-0F6C64D9840AQ57500258-D571CC2A-1B6A-459C-9742-4495CDB7428D
P2860
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Metabolism and drug interactio ...... eductase inhibitors (statins).
@ast
Metabolism and drug interactio ...... eductase inhibitors (statins).
@en
Metabolism and drug interactio ...... oenzyme A-reductase inhibitors
@nl
type
label
Metabolism and drug interactio ...... eductase inhibitors (statins).
@ast
Metabolism and drug interactio ...... eductase inhibitors (statins).
@en
Metabolism and drug interactio ...... oenzyme A-reductase inhibitors
@nl
prefLabel
Metabolism and drug interactio ...... eductase inhibitors (statins).
@ast
Metabolism and drug interactio ...... eductase inhibitors (statins).
@en
Metabolism and drug interactio ...... oenzyme A-reductase inhibitors
@nl
P2093
P356
P1476
Metabolism and drug interactio ...... eductase inhibitors (statins).
@en
P2093
P2888
P304
P356
10.1007/S002280100329
P577
2001-08-01T00:00:00Z
P6179
1012229481